



REVIEW

Bilingual edition English/Spanish

Population pharmacokinetics models of sirolimus in renal transplant patients: A systematic review

Modelos farmacocinéticos poblacionales de sirolimus en pacientes trasplantados renales: Revisión sistemática

María Remedios Candela-Boix¹, Amelia Ramón-López²,
Ricardo Nalda-Molina², Marcos Díaz-González³, Silvia Márquez-Megías⁴,
Patricio Más-Serrano^{2,3}

¹Department of Pharmacy, Hospital General Universitario, Elda (Alicante), Spain. ²Department of Engineering, Faculty of Pharmacy, Miguel Hernández University, Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain. ³Hospital General Universitario of Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain. ⁴Department of Engineering, Faculty of Pharmacy, Miguel Hernández University, Alicante, Spain.

Author of correspondence

Amelia Ramón López
Ctra. Alicante-Valencia, km 87 s/n
03012 Alicante, Spain.

Email:
aramon@umh.es

Received 16 June 2021;
Accepted 1 August 2021.
DOI: 10.7399/fh.11771

How to cite this paper

Candela-Boix MR, Ramón-López A, Nalda-Molina R, Díaz-González M, Márquez-Megías S, Más-Serrano P. Population pharmacokinetics models of sirolimus in renal transplant patients: A systematic review. *Farm Hosp.* 2021;45(Suppl 1):S77-83

Abstract

Objective: Sirolimus is used in the immunosuppressive therapeutic treatment of kidney transplant patients. The high pharmacokinetic variability of sirolimus makes pharmacokinetic monitoring and dosage individualization of immunosuppressive therapy a key process to achieve better efficacy results. The availability of a population pharmacokinetic model can be used to provide better pharmacokinetic adjustment of plasma concentrations of sirolimus and thus achieve greater clinical benefit.

Method: We conducted a systematic review of the literature available in the Medline, Embase, and Scopus databases to identify and subsequently analyze population pharmacokinetic models of orally administered sirolimus in adult patients after kidney transplant. The descriptors used MeSH were kidney transplantation, pharmacokinetics, and sirolimus. The following variables from the selected studies were assessed: study population, immunosuppressive treatment, blood sampling times, covariates analyzed, type of pharmacokinetic model, computer software used, estimated pharmacokinetic parameters, interindividual variability of pharmacokinetic parameters, residual variability and mathematical equations of the pharmacokinetic model.

Resumen

Objetivo: Sirolimus es un fármaco utilizado en los esquemas terapéuticos inmunosupresores en pacientes con trasplante renal. La elevada variabilidad farmacocinética de sirolimus hace que la monitorización farmacocinética y la individualización posológica de la terapia inmunosupresora sea un proceso crucial para conseguir mejores resultados de eficacia. La disponibilidad de un modelo farmacocinético poblacional permite realizar un mejor ajuste farmacocinético de las concentraciones plasmáticas de sirolimus y así conseguir un mayor beneficio clínico.

Método: Se realizó un análisis sistemático de la literatura disponible en las bases de datos Medline, Embase y Scopus para identificar y posteriormente analizar los modelos farmacocinéticos poblacionales de sirolimus administrado por vía oral en pacientes adultos con trasplante renal. Se utilizaron como descriptores MeSH: kidney transplantation, farmacocinetic and sirolimus. De cada artículo seleccionado se evaluó: la población a estudio, el esquema de tratamiento inmunosupresor, los tiempos de muestreo de las extracciones de sangre, las covariables analizadas, el tipo de modelo farmacocinético, el programa informático utilizado, los parámetros farmacocinéticos estimados, la variabilidad interindividual de

KEYWORDS

Kidney transplant; Pharmacokinetics; Sirolimus;
Drug monitoring; Drug dosage calculations;
Population pharmacokinetics.

PALABRAS CLAVE

Trasplante renal; Farmacocinética; Sirolimus;
Monitorización terapéutica; Dosificación de medicamentos;
Farmacocinética poblacional.



Los artículos publicados en esta revista se distribuyen con la licencia
Articles published in this journal are licensed with a
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
<http://creativecommons.org/licenses/by-nc-sa/4.0/>
La revista Farmacia no cobra tasas por el envío de trabajos,
ni tampoco por la publicación de sus artículos.

Results: A total of 548 results were obtained, excluding 175 records that were identified in more than one database. Finally, seven articles that met the inclusion criteria were selected. Most of the pharmacokinetic models found fit a two-compartment model. The interindividual variability of sirolimus was explained by covariates such as age, weight, liver function, cyclosporine exposure and dose, sirolimus doses, CYP3A5 genetic polymorphisms, serum creatinine, and concomitant treatment.

Conclusions: The two-compartment model was the pharmacokinetic model of choice in most of the selected studies. The interindividual variability of the pharmacokinetic parameters of sirolimus is explained by demographic, clinical, genetic, and biochemical variables. The availability of pharmacokinetic models of sirolimus can assist in optimizing therapy in patients after kidney transplant.

Introduction

Renal transplant is the treatment of choice for end-stage renal disease¹. Patients undergoing renal transplant need treatment with immunosuppressive therapy to prevent acute rejection and allograft loss. After transplantation, immunosuppressive treatment should be closely followed-up because these patients are more susceptible to infections, malignant neoplasms, or cardiovascular disease; comorbidities related to the underlying renal disease should be carefully monitored².

In therapeutic schemes, the main immunosuppressive agents used in combination are glucocorticoids, mycophenolate mofetil, cyclosporine, everolimus, tacrolimus, and sirolimus. Standard pharmacological treatment is based on a combination of immunosuppressive drugs with different mechanisms of action^{3,4}. This strategy minimizes the morbidity and mortality associated with each type of drug while enhancing overall efficacy. Such schemes may vary according to patient characteristics, transplant centre, or geographic area.

Sirolimus has high pharmacokinetic variability, which leads to marked differences in drug exposure in patients receiving the same dose⁵. In this context, a key and necessary process is the individualization of the dosage of immunosuppressive therapy based on pharmacokinetic monitoring to achieve the best results in terms of maximizing efficacy and safety, avoiding acute rejection, minimizing the adverse effects derived from treatment, and controlling other factors that alter the pharmacokinetic profile of the drugs, such as interactions, lack of adherence to treatment, or genetic polymorphisms.

In fact, there is a close association between exposure to sirolimus and efficacy and the appearance of adverse effects⁶. This relationship between the degree of drug exposure and safety and efficacy requires close monitoring of sirolimus plasma concentrations. It is relevant to know the factors that affect the interindividual pharmacokinetic variability of sirolimus in order to achieve the optimal individualization of drug therapy. Thus, the availability of population pharmacokinetic models of sirolimus can be used to estimate individual pharmacokinetic parameters using Bayesian methodology and make individualized pharmacokinetic adjustments to sirolimus dosing regimens, thereby achieving higher efficacy of therapy, lower rejection rates, and the lowest possible toxicity.

The aim of the present study was to conduct a systematic review of the published scientific literature on the available population pharmacokinetic models of sirolimus in renal transplant patients.

Methods

We designed a cross-sectional descriptive study and critical analysis of the scientific articles found through a systematic review. Data were obtained from the following databases: Medline (via Pubmed), Embase, and Scopus.

The bibliographic search terms were defined by consulting the *Thesaurus* developed by the U.S. National Library of Medicine. The following descriptors were considered suitable MeSH: kidney transplantation, pharmacokinetics, and sirolimus. The final search equation was designed

to be used in the Medline database via Pubmed using Boolean operators:

Resultados: Se obtuvieron un total de 548 resultados, excluyendo 175 registros tras identificarse en más de una base de datos. Finalmente se seleccionaron siete artículos que cumplían los criterios de inclusión. La mayoría de los modelos farmacocinéticos encontrados siguen un modelo bicompartimental. Covariables como edad, peso, función hepática, exposición y dosis de ciclosporina, dosis de sirolimus, polimorfismos genéticos del CYP3A5, creatinina sérica y tratamiento concomitante explican la variabilidad interindividual de sirolimus.

Conclusiones: El modelo bicompartimental fue el modelo farmacocinético de elección en la mayoría de los estudios seleccionados. La variabilidad interindividual de los parámetros farmacocinéticos de sirolimus se explica por variables demográficas, clínicas, genéticas y bioquímicas. La disponibilidad de modelos farmacocinéticos de sirolimus permiten individualizar la terapia en pacientes con trasplante renal.

ned to be used in the Medline database via Pubmed using Boolean operators:


["sirolimus"[MeSH Terms] OR "sirolimus"[Title/Abstract]] AND ("Pharmacokinetics"[MeSH Terms] OR "Pharmacokinetic"[Title/Abstract]) AND ("Kidney Transplantation"[MeSH Terms] OR "Kidney Transplantation"[Title/Abstract]).

This strategy was also designed to be used in the other databases consulted. The search was conducted until May 2021. In addition, we reviewed the scientific articles referenced by the studies selected in the final search to reduce possible publication bias. Any study found by this route was included as a manual search.

Inclusion criteria were as follows: original studies that met the objectives of the search (i.e. population pharmacokinetic models of oral sirolimus in adult renal transplant patients) that were published in peer-reviewed journals and written in English and Spanish. In addition, we included articles that could be retrieved as full text. We excluded studies that included paediatric patients as the study population and those that were not performed in humans. We also excluded communications to congresses to avoid possible duplication.

The following variables from the selected studies were assessed: study population, immunosuppressive treatment schedule, post-transplant time,

Figure 1. Flow chart of the article selection process.



blood sampling times, covariables analyzed, type of pharmacokinetic model, computer software used, estimated pharmacokinetic parameters (relative standard error), interindividual variability of pharmacokinetic parameters, residual variability, and mathematical equations of the pharmacokinetic model.

Results

The search of the three databases yielded a total of 548 results. A total of 175 records were excluded after being identified in more than one database. Finally, eight were assessed, of which one was excluded because it was a pharmacokinetic model of sirolimus as an intravenous

temsirolimus metabolite (Figure 1). No results were obtained from the manual search.

Table 1 shows the characteristics of the studies reviewed. Of the seven studies that met the inclusion criteria, five were retrospective studies (Wang *et al.*⁸, Golubovic *et al.*⁷, Dansirikul *et al.*¹², Zimmerman *et al.*⁹, and Jiao *et al.*¹⁰) and two were prospective. The studies by Jiao *et al.*¹⁰, Wang *et al.*⁸, and Ferron *et al.*¹³ were multicentre studies and the rest were single-centre studies.

Of the prospective studies, Ferron *et al.*¹³ conducted a phase I randomized double-blind placebo-controlled trial which assessed the dose-related pharmacokinetics of sirolimus (single dose of sirolimus 3, 5, 10, and 15 mg/m²). Djebli *et al.*¹¹ assessed the pharmacokinetics of sirolimus during

Table 1. Characteristics of the articles selected in the systematic review

Author/Year	Population	IS scheme	Samples	Covariates	Model	Software
Golubovic <i>et al.</i> ⁷ 2019	n = 25	SIR + MM + CO	n = 250 Trough	Age, weight, SCR, HTO, TP, TCh, TG, AST, ALT, AP, MM dose, CO dose, gender, DO, pre-tx dialysis	2C	Nonmem
Wang <i>et al.</i> ⁸ 2016	n = 22 (Healthy) n = 105 (Renal Tx)	Data obtained from three studies. 1) Bioavailability trial in healthy participants: SIR capsules/oral solution 2) Phase II trial: SIR + CsA + CO vs AZA + CsA + CO 3) Post-marketing study: SIR	n = 623 1) Trough and 0.5, 1, 2, 3, 3, 4, 6, 8, 8, 12, 16, 16, 24, 48, 72, 96, 120, 144 h post-dose 2) Trough in wk 1, 2, 4, 6, 8, 12, 16, 20, 24 after 1st dose 3) Trough in wk 1, 4, 8, 12 after 1st dose	Age, weight, height, BMI, gender, population, doses of CsA, Pc CsA, BUN, SCR, ALT, SBR	2C	Nonmem
Zimmerman <i>et al.</i> ⁹ 2016	n = 27	SIR Scheme unspecified	n = 83 Trough (Some samples 2-3 h post-dose)	Age, weight, SCR, HTO, gender, race, ≥ 1 drug interacting with SIR	2C	Nonmem
Zhen Jiao <i>et al.</i> ¹⁰ 2009	n = 112	SIR + CsA + CO for 3 mo then two groups: CsA reduction (Phase I) or CsA withdrawal (Phase II)	n = 804 - 7-10 d post-1st dose - Trough: mo 1, 3, 6, 6, 9, 12 and if acute rejection is suspected - Weekly Trough during CsA dose reduction	Age, weight, height, SC, BMI, days post-tx, SIR dose, CsA dose, Pc CsA, HDL, LDL, TC, TG, erythrocytes, leukocytes, OHT, Hb, BUN, Cr, CrCl, ALT, AST, gender, DO, co-medication	1C	Nonmem
Djebli <i>et al.</i> ¹¹ 2006	n = 22	SIR + MM + CO	n = 938 - At wk 1, 2, mo 1 and 3: Trough, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6 and 9 h post-dose - At wk 1 and 2: additionally post-12 h and 24 h	Weight, height, age, BMI, sex, SC, HTO, erythrocytes, Hb, leukocytes, AST, ALT, TCh, TG, platelets, TP, Alb, U, SCR, CYP3A5, CYP3A4 and MDR1 genotypes	2C	Nonmem
Dansirikul <i>et al.</i> ¹² 2005	n = 25	SIR + MM + CO (n = 15) SIR + CsA + CO (n = 3) SIR + TA + CO (n = 4) SIR + CO (n = 2) SIR + MM (n = 1)	n = 315 Trough	Age, SBR, Alb, HTO, weight, days post-tx, gender	2C	PKBUGS/ WinBUGS
Ferron <i>et al.</i> ¹³ 1996	n = 36	SIR (3 doses: 3, 5, 10, 15 mg/m ²) + CsA (± PRED, AZA)	n = 636 - Day 1: trough and 0.5, 1, 2, 3, 6, 12 h post-dose - Day 2: trough (except some centres on day 3 and 5)	Age, weight, height, SC, SIR dose, Pc, CsA on day 1, and study centre	2C	P-Pharm

1C: one-compartment; 2C: two-compartment; Alb: albumin; ALT: alanine transaminase; AP: alkaline phosphatase; AST: aspartate transaminase; AZA: azathioprine; BMI: body mass index; BUN: blood urea nitrogen; CO: corticosteroids; CrCl: creatinine clearance; CsA: cyclosporine; DO: donor origin; HDL: high density lipoproteins; HTO: hematocrit; IS: immunosuppressant; LDL: low density lipoproteins; MM: mycophenolate; Pc: plasma concentration; PRED: prednisone; SBR: serum bilirubin; SCR: serum creatinine; SIR: sirolimus; TA: tacrolimus; TCh: total cholesterol; TG: triglycerides; TP: total proteins; U: urea.

the first 3 months post-transplant, data were collected prospectively, and analyses was performed retrospectively. Of the retrospective studies, Jiao *et al.*¹⁰ analyzed data from a nonrandomized sequential two-phase study to assess the pharmacokinetics of sirolimus and the influence of cyclosporine (Phase 1: cyclosporine dose reduction; Phase 2: cyclosporine discontinuation elimination) during the first 12 months post-transplant. Wang *et al.*⁸ described the pharmacokinetics of sirolimus in healthy adults and renal transplant recipients. Golubovic *et al.*⁷, Dansirikul *et al.*¹², and Zimmerman *et al.*⁹ developed a pharmacokinetic model of sirolimus using clinical routine data that were obtained retrospectively.

The studies by Jiao *et al.*¹⁰ and Djebli *et al.*¹¹ included de novo renal transplant recipients at 12 and 3 months post-transplant, respectively. However, the study by Ferron *et al.*¹³ included patients with stable transplantation, compromised renal function, and high risk of rejection. The study assessed the pharmacokinetics after single oral administration of sirolimus. The study by Golubovic *et al.*⁷ included data on sirolimus (used as a second-line immunosuppressant) obtained over a 1-year period from the initiation of drug treatment. Post-transplant follow-up time was not specified. Similarly, Dansirikul *et al.*¹² and Zimmerman *et al.*⁹ included very heterogeneous patients, using a median post-transplant time of 278 months (2 days-10.7 years) and 49 months (0-202 months), respectively. Wang *et al.*⁸ included healthy volunteers (bioavailability study) and renal transplant patients (Phase II and post-marketing study), without specifying the post-transplant follow-up time.

Table 1 shows that the immunosuppression schedules of the study patients were heterogeneous. The combination of treatments included calcineurin inhibitors (cyclosporine, tacrolimus), antimetabolites (azathioprine, mycophenolate), and corticosteroids. The study by Zimmerman *et al.*⁹ did not specify the immunosuppressive regimen used in the patients. The sirolimus dosing schedule and target therapeutic range described in the included studies were as follows: Golubovic *et al.*⁷: 12-20 mg on day 1 plus simultaneous de-escalation of the first-line calcineurin inhibitor, followed by 4-8 mg (from day 2 to 5) and subsequent doses according to trough plasma concentrations (8-20 ng/mL); Djebli *et al.*¹¹: 15 mg/d on day 1 and 2 post-transplant followed by 10 mg/d for 7 days, subsequently adjusted according to plasma concentrations (10-15 ng/mL); Jiao *et al.*¹⁰: 6 mg on day 1, followed by 2 mg/d, subsequently adjusted according to plasma concentrations (6-12 ng/mL); Ferron *et al.*¹³: single doses of 3, 5, 10 and 15 mg/m² were assessed in patients on treatment with steady-state doses of cyclosporine.

The dosing schedule was not specified in the studies by Dansirikul *et al.*¹², Zimmerman *et al.*⁹, and Wang *et al.*⁸. In these studies, the reported doses were as follows: 6 ± 3 mg/d (mean ± standard deviation, range: 2-20 mg/d), 2 mg/d (median, range: 1-6 mg/d), and a dose range of 0.5 to 2 mg/d, respectively. The therapeutic interval established by Dansirikul *et al.*¹² was 4 to 12 µg/L or 12 to 20 µg/L depending on whether or not the scheme included cyclosporine, respectively. In the study by Wang *et al.*⁸ the therapeutic interval was 4-10 µg/L and in the study by Zimmerman *et al.*⁹ it varied according to the post-transplant time (0-4 months post-transplant: 10-15 µg/L; 4-12 months post-transplant: 16-24 µg/L; >12 months post-transplant: 12-20 µg/L).

Table 1 shows the sampling times. In three of the studies^{8,11,13} the pharmacokinetic analysis was conducted using full concentration-time curves, whereas in the remaining four studies^{7,9,10,12} the pharmacokinetic models were developed based on trough concentrations (pre-dose).

In six of the studies, a two-compartment model best fitted the data; only in the study by Jiao *et al.*¹⁰ was a single-compartment model used. In five of the studies the data were analyzed using NONMEM software (Icon Development Solutions, Ellicott City, USA), Ferron *et al.*¹³ used P-Pharm software (SIMED Scientific Software, Cedex, France), and Dansirikul *et al.*¹² used WinBUGS software (MRC Biostatistics Unit, Cambridge, UK).

Table 2 shows the typical values of the pharmacokinetic parameters and their estimation error (relative standard error, RSE), interindividual variability, and residual variability. Table 3 shows the mathematical equations and the covariates that explain the interindividual variability of the pharmacokinetic parameters. Most of the studies included the following covariates: age, weight, gender, height, body surface area (BSA), body mass index (BMI), cholesterol, triglycerides, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and the doses and exposure to concomitant immunosuppressants. Only the study by Djebli *et al.*¹¹ included CYP3A4, CYP3A5, and MDR1 genetic polymorphisms as covariates. The model developed by Golubovic *et al.*⁷ shows that the apparent clearance (Cl/F, where F = bioavailability) of sirolimus is influenced by age and liver function (AST). The final model of Wang *et al.*⁸ showed that Cl/F significantly decreased with increasing cyclosporin daily dose and age. In addition, the apparent peripheral volume of distribution (Vp/F) increased nonlinearly with increasing serum creatinine. Zimmerman *et al.*⁹ identified age as a covariate of Cl/F. Jiao *et al.*¹⁰ found an association between decreased Cl/F and the use of silymarin and glycyrrhizin (contained in hepatoprotective medicinal plants), the trough concentration of cyclosporine, and the total cholesterol level: however, the

Table 2. Population pharmacokinetic parameters estimated in the studies, interindividual variability, and residual variability

Parameters	Golubovic <i>et al.</i> ⁷	Wang <i>et al.</i> ⁸	Zimmerman <i>et al.</i> ⁹	Jiao <i>et al.</i> ¹⁰	Djebli <i>et al.</i> ¹¹	Dansirikul <i>et al.</i> ¹²	Ferron <i>et al.</i> ¹³
Mean parameters (RSE)							
Q/F (L/h)	5.07 (48.9)	32.9 (4.5)	27.8 (39)	NR	38.7 (14.99)	20.4 (NR)	25.2 (NR)
Cl/F (L/h)	12.2 (20.8)	8.81 (6.4)	7.4 (9)	10.1 (3)	14.1 (7.09)	12.94 (NR)	8.91 (NR)
Vc/F (L)	118 (2.15)	676 (38)	128 (29)	3,670 (9.3)	218 (7.06)	117 (NR)	112.9 (NR)
Vp/F (L)	609 (6.35)	1,380 (10.6)	278 (29)	NR	292 (10.03)	583 (NR)	452 (NR)
Ka (h ⁻¹)	2.19 (0.0022)	0.24 (7.1)	2.18	NR	5.25 (4.76)	2.195 (NR)	2.18 (NR)
t ₀ (h)	NR	NR	0.24	NR	NR	NR	0.24 (NR)
IIV (CV, %)							
Q/F	32.09	75.3	NR	NR	78.1	10.1	31.9
Cl/F	23.39	13.6	22.7	23.8	49.3	43.6	38.2
Vc/F	55.30	302.1	NR	56.7	52.7	55.2	31.8
Vp/F	25.63	15.2	NR	NR	20.2	25.6	26.4
Ka	38.08	NR	NR	NR	42.7	38.1	41.3
t ₀ (h)	NR	NR	NR	NR	NR	NR	40.1
Residual variability							
Proportional (CV, %)	49.9%	65.2%	33.8%	29.9%	242%	61.4%	NR
Additive	1.93 (ng/mL)	NR	NR	NR	3.08 (ng/mL)	NR	NR

Cl/F: apparent clearance; IIV: interindividual variability (coefficient of variation [CV] %); Ka: absorption constant; NR: not reported; Q/F: intercompartmental apparent clearance; RSE: relative standard error; t₀: latency time; Vc/F: central volume of distribution; Vp/F: peripheral volume of distribution.

Table 3. Mathematical equations of the models

Reference	Equation
Golubovic <i>et al.</i> ⁷	$Cl/F = 12.2 \times 0.63^{AST} \times (1 - \text{age}/44 \times 0.388)$ (where $AST = 0$ if $AST \leq 37$ IU/L, or $AST = 1$ if $AST > 37$ IU/L)
Wang <i>et al.</i> ⁸	$Cl/F = 8.81 \times [1 - 0.219 \times (\text{Dose CsA} / 300)] \times [1 - 0.0171 \times (\text{age} - 40)]$ $V_c/F = 676 \times (\text{SCR} / 592.3)^{1.4}$
Zimmerman <i>et al.</i> ⁹	$CL = 7.4 \times (\text{age} / 59)^{-1.02}$
Jiao <i>et al.</i> ¹⁰	$Cl/F = [10.1 - 0.662 (\text{TCh} - 5.66) - 0.00417 \times (C_{\text{troughCsA}} - 104)] \times 0.65^{SLM} \times 0.661^{GLC} \times (\text{Daily dose SIR} / 2)^{0.479}$ $V_c/F = 3670 - 7.27 \times (C_{\text{troughCsA}} - 104)$
Djebli <i>et al.</i> ¹¹	$Cl/F = 14.1 + 14.2 \times \text{CYP3A5}$
Dansirikul <i>et al.</i> ¹²	$\ln(Cl) = 2.827 - 0.2987(\text{age} / 44)$
Ferron <i>et al.</i> ¹³	$Cl = -1.55 + 0.352 \times \text{Weight}$ $V = 141.8 + 4.09 \times \text{Weight}$

AST: aspartate transaminase; CsA: cyclosporine; $C_{\text{troughCsA}}$: CsA trough concentrations; total cholesterol; DDS: daily dose sirolimus; GLC: glycyrrhizin; SCR: serum creatinine; SIR: sirolimus; SLM: silymarin.

sirolimus dose increased Cl/F in a non-linear manner. The model of Djebli *et al.*¹¹ showed an association between CYP3A5*1/*3 polymorphism and an increase in Cl/F. Dansirikul *et al.*¹² included age as a covariate inversely proportional to Cl/F. Finally, the study by Ferron *et al.*¹³ found a correlation between V_p/F and intercompartmental clearance (Q/F) and BSA and weight.

Discussion

Sirolimus is a widely used drug in the prophylaxis of solid organ rejection. It has high inter- and intra-patient pharmacokinetic variability, thus requiring periodic pharmacokinetic monitoring to adjust the dosing regimen. In the present review, the search strategy identified seven pharmacokinetic models in the literature. The cutoff for the review was May 31, 2021.

In most of the selected studies, a two-compartment model with linear elimination was the pharmacokinetic model that best fitted the data on plasma concentrations of sirolimus as a function of time. It should be noted that only in the studies by Wang *et al.*⁸, Djebli *et al.*¹¹, and Ferron *et al.*¹³ were full concentration-time curves (i.e., multiple concentrations extracted at different times after one dose per patient) available for the development of the pharmacokinetic model.

In the studies reviewed, the Cl/F values ranged from 7.4 to 14.1 L/h with no relationship in the results obtained between the models developed as a function of the amount of sampling time available in each study (full curves vs troughs alone), the sample size, or the time post-transplant (immediate transplant vs stable patients).

The sirolimus distribution volumes obtained in the seven studies were high, indicating a significant distribution of sirolimus in tissues. The values determined by the authors of the studies differed markedly from each other. Jiao *et al.*¹⁰ obtained a V_d/F of 3,670 L with an interindividual variability of 56.7%, which was much higher than that found in the other studies (range: 117-676 L). This result may be due to the use of samples taken at trough time points, which are not ideal samples for estimating distribution parameters. However, trough concentrations alone were also the only ones available in the studies by Golubovic *et al.*⁷ and Dansirikul *et al.*¹². In these studies, the values of some pharmacokinetic parameters from the study by Ferron *et al.*¹³ as "a priori" values using the "PRIOR" function were used in order to determine all the pharmacokinetic parameters of a two-compartment model. This approach would explain the lower V_c/F than that found in the study by Jiao *et al.*¹⁰. On the other hand, the values of the absorption constant (Ka) show that sirolimus has rapid absorption. Some studies^{7,9,10} fixed the value of this constant based on the value obtained in other studies due to the lack of samples-times in the absorption phase.

In the selected studies, different covariables were identified that explain some of the interindividual variability of the pharmacokinetic parameters of sirolimus. For example, most of the studies showed the clinical relevance of the variable age. Age is a factor usually assessed in pharmacokinetic studies because it affects the physiological and pathophysiological characteristics of the population, which leads to changes in drug pharmacokinetics. Age was assessed as a covariate in all the studies, but only 4 of them^{7,9,12} found an inverse relationship between age and Cl/F. This result may be because the age distribution of the population included in the other studies was very homogeneous and therefore this association was not observed.

According to Djebli *et al.*¹¹, the CYP3A5 genetic polymorphism significantly influences the Cl/F of sirolimus because it is a substrate of this enzyme¹⁴. Thus, homozygous patients with the CYP3A5*3*3 polymorphism have a lower Cl/F than patients with the CYP3A5*1*1 and CYP3A5*1*3 polymorphisms, with Cl/F being twice as high in the latter (14.1 L/h vs 28.3 L/h). However, given the limited sample size of this study, other studies with a larger sample size would be needed to support its results. Previous authors^{15,16} have also assessed the influence of CYP3A5 and CYP3A4 isoenzyme polymorphism on sirolimus pharmacokinetics. Both studies found a relationship between the two polymorphisms, although neither of these studies aimed to develop a pharmacokinetic model.

Weight has an influence on distribution parameters because of the lipophilic nature of sirolimus, which has a high partition coefficient and is partly distributed in fatty tissues. Ferron *et al.*¹³ found a correlation between body weight and BSA and apparent intercompartmental clearance (Q/F) and V_p/F .

In the model developed by Jiao *et al.*¹⁰, the sirolimus dose increased the Cl/F of sirolimus in a non-linear manner, which, according to the authors, is explained by the low bioavailability of the drug. Nevertheless, it is inadvisable to model Cl/F as a function of dose when the data used are obtained from a targeted monitoring therapy, since the correlation between sirolimus dose and Cl/F occurs because the doses are adjusted to obtain concentrations within a target range. Moreover, in the same model, the decrease in the Cl/F of sirolimus in patients with elevated total cholesterol levels could be explained by the reduction of the free fraction of sirolimus available to be metabolized.

On the other hand, Jiao *et al.*¹⁰ also found that the administration of silymarin and glycyrrhizin as concomitant treatment reduced the Cl/F of sirolimus by 34%. This effect could be explained by the inhibition of CYP3A4 and P-glycoprotein shown by both substances *in vitro*^{17,18}.

The interaction between cyclosporine and sirolimus has been studied in 2 of the pharmacokinetic models, but with little clinical impact, given that Jiao *et al.*¹⁰ observed a 4.5% decrease in the Cl/F of sirolimus for

every 100 ng/mL increase in the plasma concentration of cyclosporine, and Wang *et al.*⁸ observed a 7.3% decrease in the CL/F of sirolimus for every 100 mg increase in the daily dose of cyclosporine. This association is in line with the results of the study by Zahir *et al.*¹⁹, in which the clearance of sirolimus decreased by 20.8% per 100 mg increase in cyclosporine dose. Previous authors²⁰ have observed an interaction between cyclosporine and sirolimus at the level of absorption in healthy volunteers, with the area under the curve of sirolimus increasing by 230%. However, it should be taken into account that current guidelines^{21,22} recommend immunosuppression schemes that include triple therapy with (1) calcineurin inhibitors (tacrolimus being the drug of choice), (2) mycophenolate or mTOR inhibitor, and (3) corticosteroids. Currently, cyclosporine is little used in renal transplant programs. However, most of the population pharmacokinetic models included in the current review were based on schemes in which cyclosporine was included as an anticalcineurinic; only the model developed by Dansirikul *et al.*¹² included four patients who were administered sirolimus and tacrolimus in combination.

The inclusion of liver function, expressed as AST > 37 IU/L in the pharmacokinetic model, reached statistical significance only in the study by Golubovic *et al.*⁷, in which the CL/F of sirolimus was reduced by 37% in patients with compromised liver function. This result is in line with previous studies, which have found reductions of 31.8% and 36.0% in patients with mild and moderate hepatic impairment, respectively²³. In fact, a 50% reduction in the maintenance dose of sirolimus is recommended in patients with severe hepatic impairment²⁴.

Sirolimus is widely distributed in blood components, mainly in erythrocytes, but is sparsely distributed in plasma (< 5%). The determining factors for sirolimus to bind to red blood cells are liposolubility, the degree of ionization, molecular size, and capacity for hydrogen bonding^{5,25}. However, in

the studies reviewed, no correlation was observed between clearance and hematocrit despite its inclusion as a covariate in most of them. This result is in contrast to that observed in cancer patients treated with sirolimus²⁶, in which an inverse relationship was found between hematocrit and sirolimus clearance.

No study assessed concomitant treatment with corticosteroids as a covariate. Although the induction and inhibition interactions of corticosteroids with the metabolism and transport pathways common to immunosuppressants are known, there is little evidence of the clinical impact of the interactions^{27,28}; for this reason, it would have been interesting to include this covariate.

In conclusion, according to the available literature, the two-compartment model was the pharmacokinetic model of choice in most of the selected studies. The interindividual variability of the pharmacokinetic parameters of sirolimus is explained by variables such as age, weight, liver function, cyclosporine exposure and dose, sirolimus dose, CYP3A5 genetic polymorphisms, serum creatinine, and concomitant treatment. These results provide relevant information to optimize immunosuppressive therapy with sirolimus in renal transplant patients. However, these population pharmacokinetic models need to be validated to assess their suitability and predictive capacity before they are applied in the case of individualized dosage adjustment in specific patient populations.

Funding

No funding.

Conflict of interests

No conflict of interests.

Bibliography

1. Suthanthiran M, Strom TB. Renal transplantation. *N Engl J Med*. 1994;331:65. DOI: 10.1056/NEJM199408113310606
2. Zand MS. Immunosuppression and Immune Monitoring After Renal Transplantation. *Seminars in Dialysis*. 2005;18(6):511-9. DOI:10.1111/j.1525-139X.2005.00098.x
3. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. *Lancet*. 1999;353:1083-91. DOI: 10.1016/S0140-6736(98)07493-5
4. Halloran PH. Immunosuppressive Drugs for Kidney Transplantation. *N Engl J Med*. 2004;351:2715-29. DOI: 10.1056/NEJMra033540
5. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. *Clin Pharmacokinet*. 2001;40(8):573-85. DOI: 10.2165/00003088-200140080-00002
6. Kahan BD, Napoli KL, Kelly PA, Podbielski J, Hussein I, Urbauer DL, *et al.* Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. *Clin Transplant*. 2000;14(2):97-109. DOI: 10.1034/j.1399-0012.2000.140201.x
7. Golubovic B, Vucicevic K, Radivojevic D, Kovacevic S, Prostran M, Miljkovic B. Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients – population pharmacokinetic approach. *J Med Biochem*. 2019;38:323-33. DOI: 10.2478/jomb-2018-0030
8. Wang M, Duan B, Yuan Y, Su X, Zheng H, Wang F, *et al.* Population pharmacokinetic characteristics of sirolimus in healthy Chinese subjects and renal transplant patients. *Int J Clin Pharmacol Ther*. 2016;54(6):433-41. DOI: 10.5414/CP202499
9. Zimmerman KO, Wu H, Greenberg R, Hill K, Patel UD, Ku L, *et al.* Therapeutic drug monitoring, electronic health records, and pharmacokinetic modeling to evaluate sirolimus drug exposure response relationships in renal transplant patients. *Ther Drug Monit*. 2016;38(5):600-6. DOI: 10.1097/ftd.0000000000000313
10. Jiao Z, Shi XJ, Li ZD, Zhong MK. Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients. *Br J Clin Pharmacol*. 2009;68(1):47-60. DOI: 10.1111/j.1365-2125.2009.03392.x
11. Djebli N, Rousseau A, Hoizey G, Rerolle JP, Toupance O, Le Meur Y, *et al.* Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. *Clin Pharmacokinet*. 2006;45(11):1135-48. DOI: 10.2165/00003088-200645110-00007
12. Dansirikul C, Morris RG, Tett SE, Duffull SB. A Bayesian approach for population pharmacokinetic modelling of sirolimus. *Br J Clin Pharmacol*. 2006;62(4):420-34. DOI: 10.1111/j.1365-2125.2005.02533.x
13. Ferron GM, Mishina EV, Zimmerman JJ, Jusko WJ. Population pharmacokinetics of sirolimus in kidney transplant patients. *Int J Clin Pharmacol Ther*. 2016;54(6):433-41. DOI: 10.5414/CP202499
14. Moes D, Guchelaar HJ, De Fijter JW. Sirolimus and everolimus in kidney transplantation. *Drug Discov Today*. 2015;20(10):1243-9. DOI: 10.1016/j.drudis.2015.05.006
15. Le Meur Y, Djebli N, Szelag JC, Hoizey G, Toupance O, Rerolle JP, *et al.* CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. *Clin Pharmacol Ther*. 2006;80(1):51-60. DOI: 10.1016/j.cpt.2006.03.012
16. Anglicheau D, Le Corre D, Lechaton S, Laurent-Puig P, Kreis H, Beaune P, *et al.* Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. *Am J Transplant*. 2005;5(3):595-603. DOI: 10.1111/j.1600-6143.2005.00745.x
17. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. *Indian J Med Res*. 2006;124:491-504.
18. Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. *Drug Metab Dispos*. 2004;32(6):587-94. DOI: 10.1124/dmd.32.6.587
19. Zahir H, Keogh A, Akhlaghi F. Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids. *Ther Drug Monit*. 2006;28(5):614-22. DOI: 10.1097/01.ftd.0000246765.05248.1a
20. Zimmerman JJ, Harper D, Getsy J, Jusko WJ. Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. *J Clin Pharmacol*. 2003;43(10):1168-76. DOI: 10.1177/0091270003257227
21. Brunet M, Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, *et al.* Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. *Ther Drug Monit*. 2019;41(3):261-307.
22. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. *Am J Transplant*. 2009;9 Suppl 3:S1-155. DOI: 10.1111/j.1600-6143.2009.02834.x
23. Zimmerman JJ, Lasseter KC, Lim HK, Harper D, Dilzer SC, Parker V, *et al.* Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment. *J Clin Pharmacol*. 2005;45(12):1368-72. DOI: 10.1177/0091270005281350
24. Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica de sirolimus (Rapamune®) [Internet]. Madrid. Available at: https://cima.aemps.es/cima/dochtml/ft/01171013/FT_01171013.html
25. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. *J Pharmacokinet Pharmacodyn*. 2001;28(2):171-92. DOI: 10.1023/a:1011555016423

26. Wu K, Cohen W, House L, Ramírez J, Zhang W, Ratain MJ, *et al.* Nonlinear Population Pharmacokinetics of sirolimus in Patients With Advanced Cancer. *CPT Pharmacometrics Syst Pharmacol.* 2012;1(12):e17. DOI: 10.1038/psp.2012.18
27. Cattaneo D, Merlini S, Pellegrino M, Carrara F, Zenoni S, Murgia S, *et al.* Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing. *Am J Transplant.* 2004;4:1345-51. DOI: 10.1111/j.1600-6143.2004.00517.x
28. Jusko WJ, Ferron GM, Mis SM, Kahan BD, Zimmerman JJ. Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. *J Clin Pharmacol.* 1996;36(12):1100-6. DOI: 10.1002/j.1552-4604.1996.tb04162.x